IL115310A0 - Combination therapy for hypercholesterolemia - Google Patents
Combination therapy for hypercholesterolemiaInfo
- Publication number
- IL115310A0 IL115310A0 IL11531095A IL11531095A IL115310A0 IL 115310 A0 IL115310 A0 IL 115310A0 IL 11531095 A IL11531095 A IL 11531095A IL 11531095 A IL11531095 A IL 11531095A IL 115310 A0 IL115310 A0 IL 115310A0
- Authority
- IL
- Israel
- Prior art keywords
- hypercholesterolemia
- combination therapy
- therapy
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30890894A | 1994-09-20 | 1994-09-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL115310A0 true IL115310A0 (en) | 1995-12-31 |
Family
ID=23195885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11531095A IL115310A0 (en) | 1994-09-20 | 1995-09-14 | Combination therapy for hypercholesterolemia |
Country Status (12)
Country | Link |
---|---|
US (1) | US5807834A (xx) |
EP (1) | EP0782451A1 (xx) |
JP (1) | JPH09511753A (xx) |
AU (1) | AU2453295A (xx) |
BR (1) | BR9504072A (xx) |
CA (1) | CA2200436A1 (xx) |
FI (1) | FI971151A0 (xx) |
HR (1) | HRP950488A2 (xx) |
IL (1) | IL115310A0 (xx) |
MX (1) | MX9702175A (xx) |
WO (1) | WO1996009827A2 (xx) |
ZA (1) | ZA957879B (xx) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0737202A1 (en) * | 1993-12-28 | 1996-10-16 | Pfizer Inc. | Hypocholesterolemic agents |
MX9704683A (es) * | 1994-12-23 | 1997-09-30 | Pfizer | Inhibidores de la escualeno sintetasa. |
US5965553A (en) * | 1996-06-20 | 1999-10-12 | Pfizer Inc. | Squalene synthetase inhibitors |
US6537987B1 (en) * | 1996-06-20 | 2003-03-25 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
ATE309993T1 (de) | 1997-04-21 | 2005-12-15 | Takeda Pharmaceutical | 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten |
US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
US20030153541A1 (en) * | 1997-10-31 | 2003-08-14 | Robert Dudley | Novel anticholesterol compositions and method for using same |
TR200002774T2 (tr) * | 1998-03-26 | 2001-06-21 | Phytopharm Plc | Alzheimer hastalığının tedavisi için steroit sapogenler ve bunların türevleri |
GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
US6207664B1 (en) | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
US6465011B2 (en) | 1999-05-29 | 2002-10-15 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6372251B2 (en) | 1999-06-11 | 2002-04-16 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
GB9923077D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
GB0000228D0 (en) * | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
GB0107822D0 (en) * | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
CN102727501A (zh) * | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
PL210114B1 (pl) * | 2002-10-28 | 2011-12-30 | Phytopharm Plc | Sposób stereospecyficznego wytwarzania 3β-hydroksy-5β-H-steroidowych sapogenin |
JP4589919B2 (ja) | 2003-03-07 | 2010-12-01 | シェーリング コーポレイション | 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用 |
ATE406364T1 (de) | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
EP1699759B1 (en) | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
JP4477474B2 (ja) * | 2004-11-15 | 2010-06-09 | 株式会社日立製作所 | 糞便懸濁ろ過用容器 |
SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
BRPI0617621A2 (pt) | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4602005A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis |
US5063210A (en) * | 1989-04-20 | 1991-11-05 | Lange Iii Louis G | Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption |
CZ331094A3 (en) * | 1992-06-26 | 1995-09-13 | Pfizer | Steroidal glycosides and their use for treating hypercholesterolemia and atherosclerosis |
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
-
1995
- 1995-06-07 AU AU24532/95A patent/AU2453295A/en not_active Abandoned
- 1995-06-07 US US08/793,802 patent/US5807834A/en not_active Expired - Fee Related
- 1995-06-07 JP JP8511549A patent/JPH09511753A/ja active Pending
- 1995-06-07 MX MX9702175A patent/MX9702175A/es not_active Application Discontinuation
- 1995-06-07 EP EP95918721A patent/EP0782451A1/en not_active Withdrawn
- 1995-06-07 CA CA002200436A patent/CA2200436A1/en not_active Abandoned
- 1995-06-07 WO PCT/IB1995/000447 patent/WO1996009827A2/en not_active Application Discontinuation
- 1995-09-14 IL IL11531095A patent/IL115310A0/xx unknown
- 1995-09-19 BR BR9504072A patent/BR9504072A/pt not_active Application Discontinuation
- 1995-09-19 ZA ZA957879A patent/ZA957879B/xx unknown
- 1995-09-20 HR HR08/308,908A patent/HRP950488A2/hr not_active Application Discontinuation
-
1997
- 1997-03-19 FI FI971151A patent/FI971151A0/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX9702175A (es) | 1997-06-28 |
AU2453295A (en) | 1996-04-19 |
WO1996009827A3 (en) | 1996-05-23 |
BR9504072A (pt) | 1996-07-30 |
US5807834A (en) | 1998-09-15 |
EP0782451A1 (en) | 1997-07-09 |
JPH09511753A (ja) | 1997-11-25 |
HRP950488A2 (en) | 1997-08-31 |
ZA957879B (en) | 1997-03-19 |
FI971151A (fi) | 1997-03-19 |
CA2200436A1 (en) | 1996-04-04 |
FI971151A0 (fi) | 1997-03-19 |
WO1996009827A2 (en) | 1996-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA957879B (en) | Combination therapy for hypercholesterolemia | |
GB9421709D0 (en) | Therapeutic compounds | |
HU9700034D0 (en) | Therapeutic compounds | |
AP2002002661A0 (en) | Combination therapy for oesteoporosis | |
ZA9533B (en) | Pentolifylline therapy | |
AUPM695294A0 (en) | Improved combination therapy dose unit | |
GB9402641D0 (en) | Therapeutic agents | |
GB9410031D0 (en) | Therapeutic agents | |
GB9600143D0 (en) | Therapeutic compounds | |
GB9409264D0 (en) | Therapeutic agents | |
GB9401879D0 (en) | Therapeutic agents | |
ZA9711533B (en) | Therapeutic compounds | |
GB9403639D0 (en) | Therapeutic agents | |
GB9416629D0 (en) | Therapeutic compounds | |
GB9416632D0 (en) | Therapeutic compounds | |
SI0769017T1 (en) | Therapeutic compounds | |
GB9404379D0 (en) | Therapeutic improvement | |
GB9420340D0 (en) | Therapeutic improvement | |
GB9505272D0 (en) | Combination therapy | |
GB9605525D0 (en) | Therapy | |
GB9605466D0 (en) | Therapy | |
GB9608547D0 (en) | Therapeutic compounds | |
GB9613017D0 (en) | Therapeutic compounds | |
GB9608372D0 (en) | Therapeutic compounds | |
GB9403072D0 (en) | Therapeutic agents |